Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.70 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.70 |
| ▸ | CNR2 | P34972 | 12/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | LITAF | Q99732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919399 | 0.92 | BRD4 (0.70) | BRD4CREBBPCNR2CNR1HSD11B1 | |
| SCHEMBL4926209 | 0.92 | BRD4 (0.65) | BRD4CREBBPCNR2CNR1HSD11B1 | |
| SCHEMBL4929940 | 0.89 | BRD4 (0.66) | BRD4CREBBPCNR2CNR1HSD11B1 | |
| SCHEMBL4927737 | 0.80 | CREBBP (0.81) | BRD4CREBBPCNR2 | |
| SCHEMBL4923673 | 0.80 | BRD4 (0.67) | BRD4CREBBPCNR2CNR1PDE4A | |
| SCHEMBL4927248 | 0.79 | CREBBP (0.93) | BRD4CREBBP | |
| SCHEMBL14113972 | 0.79 | BRD4 (0.62) | BRD4CREBBPCNR2CNR1 | |
| SCHEMBL14113974 | 0.77 | BRD4 (0.51) | BRD4CREBBPCNR2CNR1 | |
| SCHEMBL4928449 | 0.77 | BRD4 (0.63) | BRD4CREBBPCNR2CNR1 | |
| SCHEMBL4914588 | 0.76 | BRD4 (0.50) | BRD4CREBBPCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CNR1, CNR2, TRPV1 | BRD4 407/4885CREBBP 3109/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.